Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment

Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment

Abstract Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type‐5 stimulation. GLP‐1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide administration.

Bibliographic Details
Main Authors: Masato Shikata, Kenji Ashida, Yuka Goto, Ayako Nagayama, Shimpei Iwata, Mamiko Yano, Nao Hasuzawa, Kento Hara, Kazutoshi Mawatari, Kiyohiko Sakata, Munehisa Tsuruta, Nobuhiko Wada, Masatoshi Nomura
Format: Article
Language:English
Published: Wiley 2020-12-01
Series:Clinical Case Reports
Subjects:
Cushing's disease
diabetes mellitus
glucagon‐like peptide‐1 receptor agonist
pasireotide
sodium‐glucose cotransporter 2 inhibitor
Online Access:https://doi.org/10.1002/ccr3.3230

Internet

https://doi.org/10.1002/ccr3.3230

Similar Items